蛋白琥珀酸铁口服溶液防治早产儿贫血的临床研究

邢燕; 童笑梅

doi:10.7499/j.issn.1008-8830.2013.12.005

PDF(1256 KB)

中国当代儿科杂志 ›› 2013, Vol. 15 ›› Issue (12) : 1059-1063. DOI: 10.7499/j.issn.1008-8830.2013.12.005

新生儿疾病专题

蛋白琥珀酸铁口服溶液防治早产儿贫血的临床研究

邢燕, 童笑梅

作者信息 +

Clinical study of iron protein succinylate oral solution for preventing and treating anemia of prematurity

XING Yan, TONG Xiao-Mei

Author information +

文章历史 +

摘要

目的评价蛋白琥珀酸铁口服溶液防治早产儿贫血的疗效和安全性。方法将60例胎龄小于35周的早产儿随机分为两组：蛋白琥珀酸铁组和多糖铁组。生后2周在应用促红细胞生成素的基础上，分别应用蛋白琥珀酸铁和多糖铁，于治疗后的14、28、42和60 d测定Hb、RBC、HCT、Ret、血清铁及铁蛋白等指标，并评价治疗前后肝肾功能的变化。结果治疗后两组间RBC和HCT变化趋势差异有统计学意义（P<0.05），蛋白琥珀酸铁组RBC和HCT均自生后逐渐降低，但分别从28 d和42 d时间点后又开始逐渐回升，而多糖铁组RBC和HCT均自生后呈现逐渐降低的趋势。在治疗后60 d，蛋白琥珀酸铁组的Hb、RBC、HCT、血清铁及铁蛋白均高于多糖铁组（P<0.05）。两组均未发生明显的不良反应。结论蛋白琥珀酸铁口服溶液在防治早产儿贫血中疗效显著，耐受性好。

Abstract

Objective To evaluate the efficacy and safety of iron protein succinylate(IPS) oral solution in preventing and treating anemia of prematurity(AOP). Methods Sixty premature infants less than 35 weeks of gestation were randomly divided into IPS(n=30) and polysaccharide iron complex(PIC) groups (n=30). Treatment began at two weeks after birth. The infants received IPS or PIC in addition to recombinant human erythropoietin. On days 14, 28, 42, and 60 after treatment, hemoglobin(Hb), red blood cell count (RBC), hematocrit(HCT), percentage of reticulocytes, serum iron, and serum ferritin were determined. Liver and renal functions were evaluated before and after treatment. Results There were significant differences in the changing trends of RBC and HCT between the two groups(P<0.05). In the IPS group, RBC and HCT gradually decreased after birth, but began to rise gradually on days 28 and 42 of treatment; in the PIC group, RBC and HCT kept decreasing from birth to day 60 of treatment. On day 60 of treatment, the IPS group had significantly higher levels of Hb, RBC, HCT, serum iron, and serum ferritin than the PIC group(P<0.05). No notable adverse events occurred in either group. Conclusions IPS oral solution has good efficacy and tolerability in preventing and treating AOP.

导出引用

邢燕, 童笑梅. 蛋白琥珀酸铁口服溶液防治早产儿贫血的临床研究[J]. 中国当代儿科杂志. 2013, 15(12): 1059-1063 https://doi.org/10.7499/j.issn.1008-8830.2013.12.005

XING Yan, TONG Xiao-Mei. Clinical study of iron protein succinylate oral solution for preventing and treating anemia of prematurity[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(12): 1059-1063 https://doi.org/10.7499/j.issn.1008-8830.2013.12.005

参考文献

[1] Steinmacher J, Pohlandt F, Bode H, Sander S, Kron M, Franz AR. Randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams: neurocognitive development at 5.3 years' corrected age[J].Pediatrics, 2007, 120(3): 538-546.
[2] Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2012, 10: CD004865.
[3] Mills RJ, Davies MW. Enteral iron supplementation in preterm and low birth weight infants[J]. Cochrane Database Syst Rev, 2012, 3: CD005095.
[4] Sifakis S, Angelakis E, Papadopoulou E, Stratoudakis G, Fragouli Y, Koumantakis E. The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy[J]. Clin Exp Obstet Gynecol, 2005, 32(2): 117-122.
[5] Careddu P, Scotti A. Controlled, double-blind, multicenter clinical trial of iron protein succinylate in the treatment of iron deficiency in children[J].Int J Clin Pharmacol Ther Toxicol, 1993, 31(4): 157-169.
[6] 邢燕, 童笑梅.贫血早产儿输血相关临床问题探讨[J]. 中华围产医学杂志, 2010, 13(2):167-169.
[7] Rosebraugh MR, Widness JA, Veng-Pedersen P. Multidose optimization simulation of erythropoietin treatment in preterm infants[J]. Pediatr Res, 2012, 71(4 Pt 1): 332-337.
[8] Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes[J]. Cochrane Database Syst Rev, 2012, 8: CD003248.
[9] Rao R, Georgieff MK. Iron therapy for preterm infants[J]. Clin Perinatol, 2009, 36(1): 27-42.
[10] Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children[J]. J Pak Med Assoc, 2009, 59(11): 764-768.
[11] Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin treated premature infants[J]. Pediatrics, 2001, 107(1): 78-85.
[12] Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1, 000 patients[J]. Int J Clin Pharmacol Ther Toxicol, 1993, 31(3): 103-123.
[13] Liu TC, Lin SF, Chang CS, Yang WC, Chen TP. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study[J]. Int J Hematol, 2004, 80(5): 416-420.
[14] Berglund S, Westrup B, Domellof M. Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants[J]. Pediatrics, 2010, 126(4): e874-883.
[15] Long H, Yi JM, Hu PL, Li ZB, Qiu WY, Wang F, et al. Benefits of iron supplementation for low birth weight infants: a systematic review[J]. BMC Pediatr, 2012, 12: 99.
[16] Jesus Cancelo-Hidalgo M, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review[J]. Curr Med Res Opin, 2013, 29(4): 291-303.